- Poster presentation
- Open access
- Published:
Clinical features of ESBL-producing E. coli responsible for bloodstream infections in French patients and molecular characterization of isolates
Antimicrobial Resistance and Infection Control volume 4, Article number: P125 (2015)
Introduction
We conducted an annually bloodstream infection (BSI) survey into hospitals overlapping the Centre France region (2.6 million). Since 2005, the incidence of BSIs associated with ESBL-producing E. coli (ESBLEc) increased.
Objectives
To improve the understanding of the pathway and the determination of the risk factors of ESBLEc-BSIs.
Methods
For each BSI, were reported patient age, sex, recent hospitalization, living in nursing home, recent antibiotherapy, urinary catheterization, BSI source, death within 7days of diagnosis.
BSI isolates were studied: antimicrobial susceptibility, determination of molecular mechanism associated with ESBL-production, genetic diversity of ESBLEc (MLST).
Results
During the survey (474,953 PDs), 443 E. coli BSI were identified, including 31 ESBLEc (7.0%; 30/31 CTX-M). Incidence of community acquired(CA)- and healthcare associated(HCA)-BSI were 0.47/100,000 and 0.040/1,000 PDs, respectively.
Major findings
For ESBLEc-CA-BSIs, male/female ratio was 1.4, median age 80, urinary BSI source in 50% of cases, recent antibiotherapy in 33 %. Most ESBLEc were resistant to fluoroquinolones (67%), SXT/TMP (67%). High genetic diversity (8 STs including 4 ST131).
For ESBLEc-HCA-BSI, male/female ratio was 0.9, median age 75, urinary BSI source in 63% of cases (recent catheterization in 1/2), recent antibiotherapy in 58%. Most ESBLEC were resistant to fluoroquinolones (79%), SXT/TMP (63%). Low genetic diversity (9 STs including 7 ST131).
Among BSI, ESBLEc-BSI were associated with healthcare (p=0.004), long-stay unit (p=0.018), recent antibiotherapy (p=0.002). ESBLEc were associated with resistance to fluoroquinolones, SXT/TMP and genta./tobramycine (p<0.001).
Among ESBLEc-BSI, clinical determinants and BSI characteristics similar whatever the clonal group excepted for ST131 associated with long-stay unit (p=0.042).
Among ST131-BSI, clinical determinants and BSI characteristics similar for ESBLEc and non ESBLEc excepted median age higher in ESBLEc (80/67).
Conclusion
Recent antibiotherapy (and easy spread into long-stay units for ST131): likely the major risk factor for ESBLEc BSI.
Disclosure of interest
None declared.
Author information
Authors and Affiliations
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made.
The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.
To view a copy of this licence, visit https://creativecommons.org/licenses/by/4.0/.
The Creative Commons Public Domain Dedication waiver (https://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
About this article
Cite this article
Gaultier, A., Girard, N., Bertrand, X. et al. Clinical features of ESBL-producing E. coli responsible for bloodstream infections in French patients and molecular characterization of isolates. Antimicrob Resist Infect Control 4 (Suppl 1), P125 (2015). https://0-doi-org.brum.beds.ac.uk/10.1186/2047-2994-4-S1-P125
Published:
DOI: https://0-doi-org.brum.beds.ac.uk/10.1186/2047-2994-4-S1-P125